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a b s t r a c t
Echinacea purpurea is one of themost popular herbal medicines and is known for its immunostimulatory
effects. Alkylamides are themain lipophilic components of E. purpurea that contribute to its pharmacolog-
ical actions. For quantiﬁcation in human plasma of one of these alkylamides, undeca-2-ene-8,10-diynoic
acid isobutylamide, a sensitive LC–MS/MS assay has been developed and validated. Plasma samples were
pretreated using liquid–liquid extractionwith amixture of diethyl ether and n-hexane (50:50, v/v). Dried
extracts were reconstituted in 50L of acetonitrile–water (50:50, v/v) after which 15L of sample was
injected into the HPLC system. HPLC was performed using a Polaris 3 C18-A column (50mm×2mm ID)
and isocratic elution with acetonitrile–water (50:50, v/v) containing 0.1% formic acid at a ﬂow rate of
0.3mL/min. Subsequently, electrospray ionization in the positive ion mode followed by tandem masssobutylamide
C–MS/MS
uman plasma
spectrometry was performed for detection. The total run time was 3min. The assay was validated over
a concentration range from 0.05 to 50ng/mL for undeca-2-ene-8,10-diynoic acid isobutylamide, with
0.05ng/mL being the lower limit of quantiﬁcation using 1.0mL plasma samples. Inter-assay inaccuracy
(±12.7%), within-day and between-day precisions (CV≤8.23%) were acceptable. Further, undeca-2-ene-
8,10-diynoic acid isobutylamidewas found to be chemically stable under relevant conditions. Finally, the
applicability of this assay has been successfully demonstrated in a pharmacokinetic experiment inwhich
ted aa human volunteer inges
. Introduction
Echinacea purpurea is one of themost popular herbalmedicines,
nd is widely used because of its supposed beneﬁcial effects on
he immune system. Examples of reported indications are the
ommon cold, ﬂu and upper respiratory infections. The active
ngredients considered responsible for the immunostimulatory and
nti-inﬂammatory actions are caffeic acid derivatives, polysaccha-
ides, glycoproteins and alkylamides [1]. Alkylamides are the main
ipophilic constituents and so far 17 structures have been identi-
ed [2]. One of the alkylamides is undeca-2-ene-8,10-diynoic acid
sobutylamide (UDAI, Fig. 1A), involved in the anti-inﬂammatory
ctivity of E. purpurea. In combination with other Echinacea alky-
amides, this compound was found to signiﬁcantly inhibit TNF-
∗ Corresponding author. Tel.: +31 30 2537377; fax: +31 30 2535180.
E-mail address: A.K.L.Goey@uu.nl (A.K.L. Goey).
570-0232 © 2010 Elsevier B.V.   
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Open access under the Elsevier OA license. commercial extract of E. purpurea.
© 2010 Elsevier B.V. 
and nitric oxide production in mouse macrophage cells [3]. Fur-
ther proof of the anti-inﬂammatory effects of UDAI was given by
Hinz et al., who demonstrated that UDAI was able to inhibit COX-
2-dependent prostaglandin E2 formation [4]. Inhibition of COX-2
has been proven to effectively suppress pain and inﬂammation. In
addition, UDAIwas also reported to inhibit T-cell IL-2 inhibition [5].
In our clinic, the potential pharmacokinetic interaction between E.
purpurea extract and ananticancer agentwill be studied inpatients.
To check the compliance of E. purpurea intake, the Echinacea alky-
lamideUDAIwas selected to bemonitored in plasma collected from
these patients. For this purpose, a bioanalytical assay has to be
developed and validated.
Until now, fewbioanalytical assays for thequantiﬁcationof alky-
Open access under the Elsevier OA license. lamides in biological matrix (plasma, serum) have been developed.
In one paper [6] a method was described for the quantiﬁcation of
eight alkylamides in human plasma using liquid chromatography
coupled with mass spectrometry (LC–MS). Solid-phase extraction
(SPE)was used for sample pretreatment. Drawbacks of thismethod
42 A.K.L. Goey et al. / J. Chromato
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fFig. 1. Chemical structures of UDAI (A) and benzanilide (B).
ere the large amount of solvents for SPE and a run time of 23min.
urthermore, this method was executed in the single ion monitor-
ng (SIM, LC–MS) mode, which is not as speciﬁc as tandem mass
pectrometry (LC–MS/MS).
Another research group has also developed LC–MS/MS meth-
ds for the bioanalysis of alkylamides in human serum and plasma
7–9]. These methods were used for evaluation of the pharmacoki-
etics of alkylamides after ingestion of Echinacea preparations by
uman volunteers. All plasma and serum samples were pretreated
singSPEbeforeperforming theLC–MS/MSanalysis.Disadvantages
f these LC–MS/MS methods were, however, a long run time of
0min per sample [7–9] and the large solvent and sample volumes
sed (14mL serum [8] and 16mL plasma [9]).
The previously described LC–MS/MS assay for UDAI, has been
sed to study the pharmacokinetics of UDAI in volunteers [7]. In
hat study, 2.5mL of an 60% ethanolic extract from the roots of Echi-
acea angustifolia was administered to 11 volunteers. The mean
aximum plasma concentration of 1.87ng/mL UDAI was found.
he LLQ of this assaywas 0.08ng/mL. In our clinical study, 20 drops
approximately 1mL) of an 65% ethanolic extract of E. purpurea
ill be administered. Compared to the pharmacokinetic study, a
ean maximum plasma concentration lower than 1.87ng/mL was
xpected due to a 2.5 times lower volume of the ingested dose.
urthermore, UDAI is more abundant in E. angustifolia than in E.
urpurea [2]. Therefore, we hypothesized that a LLQ of 0.08ng/mL
ay not be sufﬁcient for our clinical study. Furthermore, for practi-
al reasons a shorter run timeanda smaller sample volume than the
reviouslydevelopedbioanalytical assays forUDAI [6–9]wasdesir-
ble. Therefore, we have developed a fast and sensitive LC–MS/MS
ethod for the quantiﬁcation of UDAI in human plasma. In the
resent assay, liquid–liquid extraction (LLE) was used for sam-
le preparation. As no isotopically labeled internal standard was
ommercially available, benzanilide was used as internal standard
hich was also used for this purpose in previous studies (Fig. 1B)
7–10]. Further, the presently described assay has been fully val-
dated according to the FDA guidelines on Bioanalytical Method
alidation [11].
. Materials and methods
.1. Reagents and chemicals
UDAI (C15H21NO) was purchased from ChromaDex, Inc (Irvine,
A, USA). Benzanilide (C13H11NO) originated from Acros Organics
Leicestershire, UK). LC–MS grade water, ethanol and methanol of
PLCquality andacetonitrile ofHPLC-S gradient gradequalitywere
btained from Biosolve (Valkenswaard, The Netherlands). HPLC
rade n-hexane and analytical grade diethyl ether stabilized with
,6-di-tert-butyl-4-methylphenol (BHT) and formic acid were pur-
hased fromMerck (Darmstadt, Germany). Blank, drug-free human
lasma, containing heparin (Li) as anti-coagulant, was obtained
rom Innovative Research Inc. (Novi, MI, USA).gr. B 879 (2011) 41–48
2.2. Instrumentation
The LC–MS/MS equipment consisted of a DGU-14A degasser, a
CTO-10Avp columnoven, a Sil-HTc autosampler, twoLC10-ADvp-
pumps (all from Shimadzu, Kyoto, Japan) and a Finnigan TSQQuan-
tum Discovery Max triple quadrupole mass spectrometer (Thermo
Fischer Scientiﬁc, Waltham, MA, USA) with electrospray ioniza-
tion (ESI). For data acquisition and processing, Xcalibur software
(version 1.4, Thermo Fisher Scientiﬁc) was used.
2.2.1. Chromatographic conditions
Sample injections (15L) were made on a Polaris 3 C18-A col-
umn (50mm×2mmID, particle size3m,Varian,Middelburg, The
Netherlands) with a Polaris 3 C18-A pre-column (10mm×2mm
ID, particle size 3m, Varian). The column temperature was main-
tained at 40 ◦C and the autosampler was set at 15 ◦C. The total run
time was 3min. The mobile phase consisted of acetonitrile–water
(50:50, v/v) containing 0.1% formic acid, which was delivered at a
ﬂow rate of 0.3mL/min.
2.2.2. Mass spectrometry
The mass spectrometer operated in the positive ion mode with
both quadrupoles set at 0.7 full width at half height (FWHM, unit
resolution) and with dwell times of 200ms. For UDAI, the mass
transitions fromm/z232 to105wereoptimizedand forbenzanilide,
responses fromm/z 198 to 105weremonitored. The optimized col-
lision energies were −16V for UDAI and −20V for benzanilide. For
both compounds, the tube lens voltage was set at 101V. Further-
more, spray voltagewas set at 4500Vwith an ion tube temperature
of 210 ◦C. Nitrogen sheath, ion sweep and auxiliary gasses were set
at 49, 2.0 and 14 arbitrary units, respectively. Finally, the up-front
collision-induced dissociation (CID) was set off and collision gas
pressure (Ar) was set at 2.0mTorr.
The robustness of the LC–MS/MS method was tested by mon-
itoring the absolute area of UDAI and the ratio with the internal
standard for two calibration samples at the concentration level of
5ng/mL UDAI. One of these calibration samples was injected at the
beginning of a run containing 55 plasma samples in total, whereas
theother calibration samplewas injectedat theendof the samerun.
Relative standard deviations of the absolute signal of UDAI and the
ratio were calculated.
2.3. Preparation of stock and working solutions
Two stock solutions of UDAI (0.1mg/mL) from two indepen-
dent weightings were prepared in methanol. One stock solution
was used for the preparation of calibration standards, and the other
solution was used to prepare quality control (QC) samples. For the
calibration standards the stock solution was further diluted with
control human heparinized plasma to obtain working solutions in
a range from 2 to 10,000ng/mL. The stock solution for QC sam-
ples was diluted with control human plasma to obtain a working
solution of 10,000ng/mL.
For the internal standard, a stock solution of benzanilide in
methanol (1mg/mL) was further diluted with reconstitution sol-
vent (acetonitrile–water (50:50, v/v)) to obtain working solutions
of 200 and 10,000ng/mL.
The stock solutions and the internal standardworking solutions
were stored at −30 ◦C until use, while the working solutions in
plasma were used immediately after preparation.2.4. Preparation of calibration standards and QC samples in
plasma
Calibration standards were prepared freshly by diluting plasma
working solutions with human plasma to obtain concentrations of
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.05, 0.1, 1, 5, 25 and 50ng/mL UDAI. These standards were pre-
ared and analyzed in duplicate.
QCsampleswereprepared inbatchesbydiluting theQCworking
olution in volumetric ﬂasks, obtaining QC samples at concentra-
ions of 0.05 (LLQ), 0.15 (low), 5 (mid), 40 (high) and 50 (upper limit
f quantiﬁcation: ULQ) ng/mL UDAI. As no plasma concentrations
f UDAI higher than 50ng/mLwere expected in patient samples, no
ilution test sample above the ULQ (>ULQ sample) was prepared.
C samples were stored at −30 ◦C until analysis.
.5. Sample preparation
To 1mL plasma samples 50L of the internal standard ben-
anilide (200ng/mL) was added in a conical glass tube. After
ortex-mixing, LLE was performed with 8mL diethyl ether/n-
exane (50:50, v/v). Subsequently, the sampleswere shakenwith a
otary-mixer for 10min at 50 rpm. After centrifugation for 10min
t 3200× g (4 ◦C), the samples were stored at −30 ◦C for 60min.
ext, the organic layerwasdecanted into another conical glass tube
nd evaporized under a stream of nitrogen at 40 ◦C. The residue
as reconstituted in 50L of acetonitrile–water (50:50, v/v) and
ortex-mixed for approximately 15 s. After transferring the solu-
ion into 1.5mL Eppendorf tubes the solution was centrifuged for
0minat 13,500 rpm. Finally, the clear supernatantwas transferred
nto a 250L glass insert placed in an autosampler vial.
. Validation procedures
A full validation of the assay in human heparinized plasma was
erformed according to the current FDAguidelines onBioanalytical
ethod Validation [11].
.1. Linearity
Six non-zero calibration standards at concentrations of 0.05,
.1, 1, 5, 25 and 50ng/mL UDAI were prepared freshly in dupli-
ate for each run and analyzed in three separate runs. Calibration
urves (ratio of the areas of the analyte and internal standard peaks
ersus the nominal concentration) were ﬁtted by least-squares lin-
ar regression and the reciprocal of the squared concentration
1/x2) was used as a weighting factor.
Deviations from the nominal concentrations should be within
20% for the LLQ and within ±15% for the other concentrations.
.2. Accuracy and precision
Accuracy and precision of the assaywere determined by analyz-
ng ﬁve replicates of QC samples of UDAI at the LLQ, low, mid and
igh concentration levels together with duplicate calibration stan-
ards in three analytical runs. Inter-assay accuracy was calculated
s the relative difference between the mean measured concen-
ration after the three runs and the nominal concentration. The
ccuracy shouldbewithin 80–120% for the LLQand85–115% for the
ther concentrations. Intra- and inter-assay precisions were repre-
ented by the coefﬁcient of variation (CV%), which should be less
han 20% for the LLQ and less than 15% for the other concentrations.
.3. Recovery and ion suppression
For the determination of ion suppression (matrix effect), 1mL
f blank human plasma was processed as a double blank plasma
ample. After LLE and evaporation (as described in Section 2.5), the
xtracts were reconstituted with 50L of reconstitution solvent.
hree different concentrations of reconstitution solvents (all pre-
ared in acetonitrile–water (50:50, v/v)) were added in triplicate:
olvent 1 (3ng/mL UDAI +200ng/mL internal standard), solventgr. B 879 (2011) 41–48 43
2 (100ng/mL UDAI +200ng/mL internal standard) and solvent 3
(800ng/mL UDAI +200ng/mL internal standard).
For calculation of ion suppression, the analytical response of
the reconstituted extracts was compared with the response of the
directly injected reconstitution solvents (1, 2 and 3).
For the extraction recovery study, QC samples (0.15, 5 and
40ng/mL UDAI) were prepared according to Section 2.5. The
ﬁnal concentration of UDAI in these QC samples was 3, 100 and
800ng/mL (due to the 20 times concentration factor during sample
preparation).
The analytical response of these QC samples was compared to
the response of the blank plasma extracts reconstituted with the
solvents 1, 2 and 3 mentioned above.
Determination of the overall recovery was performed by com-
paring the analytical response of the processed QC samples (0.15,
5 and 40ng/mL) to the response of unprocessed reconstitution sol-
vents 1, 2 and 3.
3.4. Carry-over
Carry-over was assessed by injecting two processed blank
plasma samples immediately after injecting a sample at the ULQ
(50ng/mL). The response of the ﬁrst blank sample at the retention
time of UDAI should be less than 20% of the response of a processed
LLQ sample.
3.5. Speciﬁcity and selectivity
Potential interference between analyte and endogenous matrix
components was investigated by analyzing six batches blank
human plasma from different origin. From each batch, a double
blank and a LLQ sample were prepared, processed and analyzed
according to the described procedures. To assess potential interfer-
ence between internal standard and analyte, blank samples spiked
separately with analyte (at the ULQ) and internal standard were
processed and analyzed.
Peak areas of compounds co-eluting with UDAI should be less
than 20% of the peak area of the LLQ sample. Areas of peaks that
co-elute with the internal standard, should not exceed 5% of the
mean internal standard peak area.
The calculated concentrations of the LLQ samples should not
deviate more than 20% from the nominal concentrations.
3.6. Stability
Stability of stock solutions of UDAI and internal standard was
determined by analyzing aliquots of stock solutions in triplicate
which were kept at room temperature for 24h. Peak areas of these
samples were compared with those of stock solutions that were
stored at −30 ◦C and represented freshly prepared stock solutions.
Furthermore, stability of UDAI stock solution was assessed after
storage for 2 months at −30 ◦C.
Todetermine short-termtemperature stability,QCsampleskept
at room temperature for 6h were analyzed in triplicate and com-
pared to the initial concentrations.
Long-term stability of UDAIwas determined in triplicate by ana-
lyzing QC samples after storage at −30 ◦C.
Freeze (−30 ◦C)/thawstability ofUDAI inhumanheparinplasma
was assessed by comparing QC samples after three freeze/thaw
cycles with the concentrations determined at time zero.
Stability of reconstituted extracts was assessed in quadrupli-
cate after storage for 48h at 2–8 ◦C and compared with the initial
concentrations.
QC samples analyzed in the above mentioned stability exper-
iments were prepared at two concentration levels: 0.15 and
40ng/mL UDAI. Concentrations of UDAI in the biological matrix
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Fig. 2. (A) MS/MS product ion scan of UDAI (precursor ion m/z 232). (B) MS/MS product ion scan of benzanilide (precursor ion m/z 198).
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Aig. 3. Representative LC–MS/MS chromatograms of a blank human heparinized pl
f 0.05ng/mL (A2, UDAI, tr = 1.6min; B2, internal standard benzanilide, tr = 1.2min)
amples should not deviate more than 15% from the initial con-
entrations. UDAI and internal standard were considered stable in
tock solution if 95–105% and 80–120% of the initial peak area is
ecovered for UDAI and benzanilide, respectively.
. Results and discussion
.1. Mass spectrometry
The protonated molecule of UDAI at m/z 232 was used to gen-
rate a product ion spectrum. For selected reaction monitoring
SRM), the most abundant fragment ion (m/z 105) was selected
nd the fragmentation conditions were optimized. The condi-
ions of m/z 198–105 were optimized for monitoring the internal
tandard benzanilide. MS/MS product scans and the proposed
ragmentation pathways of UDAI and benzanilide are depicted in
ig. 2..2. Chromatography
Woelkart et al. developed a method using a reversed phase col-
mn and the analyteswere eluted from the columnwith a gradient
onsisting of 0.1% formic acid in water (mobile phase A) and 0.1%
able 1
ssay performance data for UDAI (n=15).
Nominal concentration
(ng/mL)
Mean measured concentration
(ng/mL, ±SD)
Inter-assay accur
0.0500 0.0533 (±0.00454) 107
0.150 0.163 (±0.00686) 108
5.00 5.17 (±0.155) 103
40.0 34.9 (±1.27) 87.3sample (A1, B1) and of a spiked human heparinized plasma sample at the LLQ level
formic acid in acetonitrile (mobile phase B) [7–9]. A ﬂow rate of
0.25–0.3mL/minwas used [7–10].We have tested isocratic elution
(A:B (50:50, v/v)) at a ﬂow rate of 0.3mL/min to shorten the total
run time. These conditions resulted in symmetric peaks and a total
run time of only 3min. Representative chromatograms of a blank
sample and a human plasma sample spiked at the LLQ are given
in Fig. 3. In the robustness test, the relative standard deviation of
the absolute area of UDAI was less than 2% and less than 5% for the
ratio with the internal standard, demonstrating the robustness of
the method.
4.3. Sample pre-treatment
After administration of a single oral dose of an ethanolic extract
of E. angustifolia to 11 healthy volunteers, a Cmax of 1.87ng/mL in
plasmawas found for UDAI [7]. This ﬁnding indicated the need for a
sensitive bioanalytical assay. Clean sample extracts were required
to achieve a LLQ of 0.05ng/mL. LLE was tested in the present
study. Several ratios of diethyl ether/n-hexane were investigated:
the highest overall recovery was found for diethyl ether/n-hexane
(50:50, v/v).
Subsequently, the optimal volume of diethyl ether/n-hexane
(50:50, v/v) was assessed by LLE with organic phase volumes rang-
acy (%) Within-day precision (% CV) Between-day precision (% CV)
7.99 8.23
3.71 4.08
2.56 2.90
2.89 3.51
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roduct ion scan of UDAI (tr = 1.67min) of the human plasma sample at t=60min. P
ng from 2 to 9mL and selecting the volume with the highest
bsolute MS/MS response of analyte and internal standard. Eight
illiliters of diethyl ether/n-hexane (50:50, v/v) was found to give
he best results and was therefore selected..4. Validation
.4.1. Linearity
The assay was linear over a concentration range of
.05–50ng/mL for UDAI in human plasma.60min after ingestion of 20 drops of A. Vogel Echinaforce® (t=60min). (B) MS/MS
ed chemical structures are depicted for product ions m/z 91, 105, 131 and 176.
Using least-squares linear regression (area ratio versus the con-
centration) with a weighting factor of 1/x2, the lowest total bias
and the most constant bias across the range were obtained. The
average regression parameters of the linear regression functions
(n=3) were y=7.97×10−5(±6.30×10−5) + 0.0292(±0.0176)xwith
an average correlation coefﬁcient of 0.994(±0.00395).At all concentration levels deviations ofmeasured fromnominal
concentrationswerebetween−17.9 and8.15% for LLQandbetween
−12.2 and 12.1% at the other concentration levels. CV values varied
between 3.46 and 18.1% at LLQ and between 0.148 and 12.4% at the
remaining concentration levels.
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Table 2
Stability data for UDAI and the internal standard benzanilide.
Conditions Matrix Initial concentration
(ng/mL)
Found concentration
(ng/mL)
Dev (%) CV (%) No. of
replicates
UDAI
Ambient, 24h Methanol 1.10×105 1.14×105 4.12 17.4 3
−30 ◦C, 2 months Methanol 1.01×105 1.07×105 5.52 3.04 3
Ambient, 6h Plasma 0.154
41.2
0.163
44.5
5.58
8.01
6.97
3.03
3
3
−30 ◦C, 1 month Plasma 0.176
40.4
0.188
44.1
7.28
8.93
13.7
6.25
3
3
3 freeze (−30 ◦C)/thaw cycles Plasma 0.154
41.2
0.159
40.6
3.31
−1.33
2.53
4.91
3
3
2–8 ◦C, 48h Final extract 0.154
5.15
41.2
0.145
4.87
37.5
−6.09
−5.40
−9.07
5.20
1.87
5.66
4
4
4
Benzanilide
Ambient, 24h Methanol 9.70×105 9.04×105 −6.84 12.1 3
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c−30 ◦C, 4 months Methanol 1.07×106
ev: deviation from the initial concentration and CV: coefﬁcient of variation.
.4.2. Accuracy and precision
Assay performance data for UDAI in human plasma are summa-
ized in Table 1. The inter-assay inaccuracy was within ±12.7% for
ll concentrations, thus meeting the required ±15% (±20% for LLQ)
11]. The within-day and between-day precisions did not exceed
.23% for all concentrations and therefore fulﬁlled the required
riterion of ±15% (±20% for LLQ) [11].
.4.3. Recovery and ion suppression
Ion suppression has been demonstrated for both UDAI and ben-
anilide. The mean ion suppression for UDAI was −15.0% (range
22.0 to −8.60%), and for benzanilide a mean ion suppression of
14.1% (range −19.8 to −11.2%) was observed.
After comparing the analytical response of processed QC sam-
les to that of blank processed plasma samples reconstituted
ith solutions containing analyte and internal standard, mean LLE
ecoveries of 53.5 and 62.8% were found for UDAI and benzanilide,
espectively.
The mean total recovery was 45.5% for UDAI and 53.9% for ben-
anilide and were found to be reproducible.
.4.4. Carry-over
In the ﬁrst processed blank, the carry-over was 6.84 and
.687% of the areas of the compounds in a processed LLQ sam-
le for UDAI and benzanilide, respectively. These percentageswere
ar below the required 20% and were thus found to be accept-
ble.
.4.5. Speciﬁcity and selectivity
SRM chromatograms of six batches of control drug-free hep-
rinized plasma contained no co-eluting peaks >20% of the analyte
eak area at the LLQ level, andno co-eluting peaks >5%of the area of
he internal standard. The six batches showed deviations from the
ominal concentrations at the LLQ level between −12.9 and 19.6%
or UDAI and were approved.
Further, no cross-analyte/internal standard interference was
bserved, as no peaks were detected at the retention time of
DAI when analyzing a sample containing only internal stan-
ard. Additionally, no peaks were detected at the retention time
f benzanilide when a sample containing only UDAI was pro-
essed.1.16×106 8.49 3.25 3
4.4.6. Stability
The stability data forUDAI and the internal standardbenzanilide
are summarized in Table 2. These data show that stock solutions of
UDAI and benzanilide were stable for at least 24h at ambient tem-
peratures. The stock solution of benzanilide was stable for at least
4 months at −30 ◦C. After storage for 2 months at −30 ◦C, the stock
solution of UDAI was just outside the range of 95–105% recovery
of the initial measured concentration, indicating that UDAI in stock
solution is stable for up to 2 months under the tested conditions.
Short-term stability experiments demonstrated stability of
UDAI in human heparinized plasma at ambient temperatures for
at least 6h.
Regarding long-term stability, UDAI was stable in plasma for up
to 1 month at −30 ◦C.
Freeze/thaw stability experiments showed that UDAI was
stable in human heparinized plasma for at least three freeze
(−30 ◦C)/thaw cycles.
Finally, in the ﬁnal extract stability of UDAI was demonstrated
for at least 48h at 2–8 ◦C.
5. Application of the method
To demonstrate the applicability of the present assay, a sin-
gle pharmacokinetic experiment was conducted in which a human
volunteer ingested a single low dose of 20 drops of a commercial
extract ofE. purpurea (Echinaforce®, A. Vogel). ThepresenceofUDAI
was detected in the blood sample taken at 60min (Fig. 4A). The
identity of UDAI was conﬁrmed by the retention time of the peak
at 1.6min, absent in the blank sample, and which correlates with
that of the reference standard of UDAI. Additionally, in the product
ion spectrum of m/z 232 at 16.0V the major product ions m/z 91,
105, 131 and 176 were observed (Fig. 4B) which are identiﬁed as
those in the reference compound of UDAI (Fig. 2A). The plasma con-
centration of UDAI at t=60min was quantiﬁed as 0.060ng/mL. The
chromatogram and product ion scan of UDAI in the human sample
at t=60min are depicted in Fig. 4.
6. ConclusionsThis paper describes the development, validation and applica-
tion of a LC–MS/MS assay for the quantitative analysis of UDAI in
human plasma. This is the ﬁrst quantitative assay for an alkylamide
which has been fully validated according to the FDA guidelines
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(2009) 1306.
[11] U.S. Department of Health and Human Services, Food and Drug Adminis-
tration, Center for Drug Evaluation and Research, Guidance for Industry:
Bioanalytical Method Validation, May, 2001, http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.8 A.K.L. Goey et al. / J. Chr
n Bioanalytical Method Validation [11]. To extract UDAI from
uman plasma, a LLE method was performed. Validation results
how that this assay is accurate, precise, selective and repro-
ucible. Using 1mL of plasma aliquots, a concentration range from
.05 to 50ng/mL UDAI could be quantiﬁed. This sample volume is
ess than used in previously published LC–MS/MS assays for alky-
amides of E. purpurea in biological matrices. Furthermore, with a
LQ of 0.05ng/mL this assay is more sensitive than the previously
escribed bioanalytical assay for UDAI in human plasma [7]. At last,
n the pharmacokinetic experiment a peak plasma concentration of
.06ng/mL UDAI was measured 60min after ingestion of 20 drops
f a commercial extract of E. purpurea. This low concentration of
DAI demonstrated the need for the present, sensitive, assay for
DAI to be used in the clinical study. In our clinical trial, how-
ver, we expect to detect higher levels of UDAI in patients, as the
atients will use the extract more frequently than our volunteer:
times daily 20 drops during a period of 14 days. Thus, this phar-
acokinetic experiment showed that the LLQwas sufﬁcient for our
urpose tomonitor the adherenceofE. purpurea in a clinical setting.cknowledgement
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